DIANTHUS THERAPEUTICS INC (DNTH) — insider trading
Health Care · NASDAQ
DIANTHUS THERAPEUTICS INC (DNTH) has 89 reported SEC Form 4 insider transactions in our data, including 40 open-market sales among the most recent 89 (latest 2026-09-17).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | CARR EDWARD | Officer (CHIEF ACCOUNTING OFFICER) | Option exercise / conversion (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-09-17 | CARR EDWARD | Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | 700 | $104.39 | $73.1K | Form 4 |
| 2026-09-17 | CARR EDWARD | Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | 1,100 | $103.20 | $113.5K | Form 4 |
| 2026-09-17 | CARR EDWARD | Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | 3,501 | $102.39 | $358.5K | Form 4 |
| 2026-09-17 | CARR EDWARD | Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | 6,771 | $101.37 | $686.4K | Form 4 |
| 2026-09-17 | CARR EDWARD | Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | 7,928 | $100.43 | $796.2K | Form 4 |
| 2026-09-17 | CARR EDWARD | Officer (CHIEF ACCOUNTING OFFICER) | Option exercise / conversion | 20,000 | $17.88 | $357.6K | Form 4 |
| 2026-09-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 9,375 | — | $0 | Form 4 |
| 2026-09-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 6,249 | — | $0 | Form 4 |
| 2026-09-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-09-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Open-market sale | 13,309 | $106.74 | $1.42M | Form 4 |
| 2026-09-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Open-market sale | 7,215 | $106.25 | $766.6K | Form 4 |
| 2026-09-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Open-market sale | 2,600 | $105.19 | $273.5K | Form 4 |
| 2026-09-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 9,375 | $22.07 | $206.9K | Form 4 |
| 2026-09-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 6,249 | $21.77 | $136.0K | Form 4 |
| 2026-09-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 7,500 | $17.88 | $134.1K | Form 4 |
| 2026-08-19 | Read Simon | Director | Option exercise / conversion (derivative) | 2,778 | — | $0 | Form 4 |
| 2026-08-19 | Read Simon | Director | Open-market sale | 2,778 | $117.55 | $326.6K | Form 4 |
| 2026-08-19 | Read Simon | Director | Option exercise / conversion | 2,778 | $18.36 | $51.0K | Form 4 |
| 2026-08-13 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Option exercise / conversion (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-08-13 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Option exercise / conversion | 15,000 | $18.17 | $272.6K | Form 4 |
| 2026-08-10 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Option exercise / conversion (derivative) | 16,167 | — | $0 | Form 4 |
| 2026-08-10 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Open-market sale | 16,167 | $110.38 | $1.78M | Form 4 |
| 2026-08-10 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Option exercise / conversion | 16,167 | $17.88 | $289.1K | Form 4 |
| 2026-08-10 | Read Simon | Director | Option exercise / conversion (derivative) | 2,777 | — | $0 | Form 4 |
| 2026-08-10 | Read Simon | Director | Open-market sale | 397 | $111.77 | $44.4K | Form 4 |
| 2026-08-10 | Read Simon | Director | Open-market sale | 470 | $111.05 | $52.2K | Form 4 |
| 2026-08-10 | Read Simon | Director | Open-market sale | 272 | $109.96 | $29.9K | Form 4 |
| 2026-08-10 | Read Simon | Director | Open-market sale | 831 | $108.95 | $90.5K | Form 4 |
| 2026-08-10 | Read Simon | Director | Open-market sale | 737 | $108.17 | $79.7K | Form 4 |
| 2026-08-10 | Read Simon | Director | Open-market sale | 70 | $107.11 | $7.5K | Form 4 |
| 2026-08-10 | Read Simon | Director | Option exercise / conversion | 2,777 | $18.36 | $51.0K | Form 4 |
| 2026-08-10 | McGeorge Anne | Director | Option exercise / conversion (derivative) | 6,500 | — | $0 | Form 4 |
| 2026-08-10 | McGeorge Anne | Director | Option exercise / conversion (derivative) | 1,250 | — | $0 | Form 4 |
| 2026-08-10 | McGeorge Anne | Director | Open-market sale | 700 | $111.41 | $78.0K | Form 4 |
| 2026-08-10 | McGeorge Anne | Director | Open-market sale | 1,000 | $110.64 | $110.6K | Form 4 |
| 2026-08-10 | McGeorge Anne | Director | Open-market sale | 1,800 | $109.30 | $196.7K | Form 4 |
| 2026-08-10 | McGeorge Anne | Director | Open-market sale | 2,800 | $108.38 | $303.5K | Form 4 |
| 2026-08-10 | McGeorge Anne | Director | Open-market sale | 1,450 | $107.58 | $156.0K | Form 4 |
| 2026-08-10 | McGeorge Anne | Director | Option exercise / conversion | 6,500 | $11.20 | $72.8K | Form 4 |
| 2026-08-10 | McGeorge Anne | Director | Option exercise / conversion | 1,250 | $19.36 | $24.2K | Form 4 |
| 2026-08-07 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Option exercise / conversion (derivative) | 3,833 | — | $0 | Form 4 |
| 2026-08-07 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Open-market sale | 616 | $111.18 | $68.5K | Form 4 |
| 2026-08-07 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Open-market sale | 3,217 | $110.61 | $355.8K | Form 4 |
| 2026-08-07 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Option exercise / conversion | 3,833 | $17.88 | $68.5K | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Option exercise / conversion (derivative) | 126,000 | — | $0 | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Option exercise / conversion (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Open-market sale | 21,909 | $108.72 | $2.38M | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Open-market sale | 104,091 | $107.96 | $11.24M | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Open-market sale | 800 | $110.76 | $88.6K | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Open-market sale | 2,536 | $110.02 | $279.0K | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Open-market sale | 2,373 | $109.10 | $258.9K | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Open-market sale | 23,907 | $108.05 | $2.58M | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Open-market sale | 10,384 | $107.49 | $1.12M | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Option exercise / conversion | 126,000 | $8.44 | $1.06M | Form 4 |
| 2026-08-07 | Garcia Marino | Director, Officer (CEO AND PRESIDENT) | Option exercise / conversion | 40,000 | $8.44 | $337.6K | Form 4 |
| 2026-07-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Option exercise / conversion (derivative) | 31,249 | — | $0 | Form 4 |
| 2026-07-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Open-market sale | 5,566 | $101.97 | $567.6K | Form 4 |
| 2026-07-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Open-market sale | 15,329 | $101.24 | $1.55M | Form 4 |
| 2026-07-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Open-market sale | 10,354 | $100.22 | $1.04M | Form 4 |
| 2026-07-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Option exercise / conversion | 31,249 | $21.77 | $680.3K | Form 4 |
| 2026-06-17 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Option exercise / conversion (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-17 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Open-market sale | 13,229 | $81.38 | $1.08M | Form 4 |
| 2026-06-17 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Open-market sale | 16,771 | $80.34 | $1.35M | Form 4 |
| 2026-06-17 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Option exercise / conversion | 30,000 | $17.88 | $536.4K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 9,375 | — | $0 | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 6,249 | — | $0 | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 6,908 | — | $0 | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 3,998 | — | $0 | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Open-market sale | 4,159 | $91.37 | $380.0K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Open-market sale | 16,943 | $90.72 | $1.54M | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Open-market sale | 5,428 | $89.72 | $487.0K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 9,375 | $22.07 | $206.9K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 6,249 | $21.77 | $136.0K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 6,908 | $17.88 | $123.5K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 3,998 | $8.44 | $33.7K | Form 4 |
| 2026-05-21 | Soteropoulos Paula | Director | Grant / award / vesting (derivative) | 6,090 | — | $0 | Form 4 |
| 2026-05-21 | Violin Jonathan | Director | Grant / award / vesting (derivative) | 6,090 | — | $0 | Form 4 |
| 2026-05-21 | KANGO SUJAY | Director | Grant / award / vesting (derivative) | 6,090 | — | $0 | Form 4 |
| 2026-05-21 | Lawton Alison Frances | Director | Grant / award / vesting (derivative) | 6,090 | — | $0 | Form 4 |
| 2026-05-21 | McGeorge Anne | Director | Grant / award / vesting (derivative) | 6,090 | — | $0 | Form 4 |
| 2026-05-21 | Romano Steven J. | Director | Grant / award / vesting (derivative) | 6,090 | — | $0 | Form 4 |
| 2026-05-21 | Read Simon | Director | Grant / award / vesting (derivative) | 6,090 | — | $0 | Form 4 |
| 2026-05-08 | Soteropoulos Paula | Director | Option exercise / conversion (derivative) | 599 | — | $0 | Form 4 |
| 2026-05-08 | Soteropoulos Paula | Director | Open-market sale | 599 | $85.47 | $51.2K | Form 4 |
| 2026-05-08 | Soteropoulos Paula | Director | Option exercise / conversion | 599 | $8.44 | $5.1K | Form 4 |
| 2026-04-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Option exercise / conversion (derivative) | 8,224 | — | $0 | Form 4 |
| 2026-04-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Open-market sale | 8,224 | $89.84 | $738.8K | Form 4 |
| 2026-04-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Option exercise / conversion | 8,224 | $17.88 | $147.0K | Form 4 |
Ask the chat about DNTH's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: DIANTHUS THERAPEUTICS INC (DNTH).
Last updated 2026-09-17 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.